Skip to main content
海昇药业 logo

海昇药业 — Investor Relations & Filings

Ticker · 920656 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 271 across all filing types
Latest filing 2024-03-25 Governance Information
Country CN China
Listing Beijing Stock Exchange 920656

About 海昇药业

https://www.zcpc.net/

Zhejiang Haisheng Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes antipyretic and analgesic medications, cardiovascular agents, and various specialty chemical intermediates. It is recognized as a major global supplier of Naproxen and Naproxen Sodium. Haisheng Pharmaceutical maintains rigorous quality control systems compliant with international standards, including Good Manufacturing Practice (GMP) certifications. The company serves a diverse global clientele, providing high-purity chemical components essential for finished dosage form manufacturing. Its technical expertise focuses on chemical synthesis and process optimization to ensure stable supply chains for the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
浙江海昇药业股份有限公司关联交易管理制度
Governance Information Classification · 95% confidence The document is titled as a management system for related party transactions of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the principles, definitions, decision-making procedures, pricing management, and supervisory responsibilities related to related party transactions. The document includes internal governance rules and procedures rather than financial results, audit opinions, or announcements of voting results. It is a detailed governance-related policy document issued by the board and approved by the shareholders. There is no indication that this is an announcement of a report publication or a short notice. The content fits the description of Governance Information (CGR), which covers internal rules, board structure, and governance practices.
2024-03-25 Chinese
长江证券承销保荐有限公司关于浙江海昇药业股份有限公司使用银行承兑汇票及自有资金等方式支付募投项目所需资金并以募集资金等额置换的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution regarding the use of bank acceptance bills and own funds to pay for a fundraising investment project and the equivalent replacement with raised funds. It references regulatory approvals, fundraising amounts, and compliance with listing rules on the Beijing Stock Exchange. The document includes descriptions of the fundraising, usage of funds, board approvals, and the sponsor's verification opinion. It is not a full financial report like an Annual Report or Interim Report, nor is it a brief announcement or a certification letter. It is a regulatory compliance and verification report related to fundraising and capital use, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories such as Capital/Financing Update (CAP) or Audit Report (AR). The document length is under 5,000 characters, but it contains substantive content rather than just an announcement of a report publication, so it is not RPA. Therefore, the best classification is Regulatory Filings (RNS).
2024-03-25 Chinese
关于相关股东延长锁定期的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the extension of the lock-up period for certain shareholders following the company's public stock issuance and listing on the Beijing Stock Exchange. It details commitments by controlling shareholders, actual controllers, directors, supervisors, and senior management about restrictions on share transfers and lock-up periods. The document includes specific dates, shareholder names, share quantities, and extended lock-up deadlines. There is no financial statement, earnings data, or management discussion of financial results. The content is focused on shareholder lock-up commitments and regulatory compliance related to shareholding restrictions post-IPO. This type of announcement fits best under the category of Regulatory Filings (RNS), as it is a regulatory disclosure about shareholder lock-up commitments and not a financial report or other specific filing type.
2024-03-10 Chinese
关于公司股东完善稳价措施的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the company's shareholder measures to stabilize stock price, including a commitment letter from the actual controllers to extend the lock-up period of restricted shares and to support dividend distribution proposals. It details shareholding and lock-up extension specifics, commitments to investor relations, and governance improvements. There is no financial data, no report attached or referenced as published, and no mention of a meeting or voting results. The document is a regulatory announcement about shareholder commitments and stock lock-up measures, which fits best under Regulatory Filings (RNS) as it does not match other specific categories like capital changes, director dealings, or dividend notices directly. The document length is short (1570 characters), and it is not a report or presentation but a formal announcement of shareholder commitments and company governance measures.
2024-03-10 Chinese
第三届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 13th meeting of the third board of directors of Zhejiang Haisheng Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda, voting results, and compliance with legal and procedural requirements. There is no financial data, earnings information, or report publication mentioned. The content focuses on board meeting decisions and governance matters, specifically the approval of a price stabilization measure. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board of directors or senior management.
2024-03-10 Chinese
关于拟调整稳价措施暨致歉的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Zhejiang Haisheng Pharmaceutical Co., Ltd. regarding the proposed adjustment of stock price stabilization measures and an apology to investors. It mentions the application by the actual controllers to adjust stock lock-up periods and improve investor returns. The document is short (501 characters) and does not contain financial statements, detailed financial data, or regulatory certifications. It is not a report itself but an announcement about corporate governance and investor relations measures. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is also not a Board/Management change announcement but relates to capital market measures and investor protection. The best fitting category is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2024-03-04 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.